ico Therapeutics Andrew Rae, President & CEO / TSX-V: ICO
|
|
- Thomasina Powell
- 5 years ago
- Views:
Transcription
1 ico Therapeutics Andrew Rae, President & CEO / TSX-V: ICO
2 Forward Looking Statements Certain of the statements contained in this presentation are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. 2
3 About ico Therapeutics Targeting ocular diseases Lead program: Pipeline: Partnerships: Ph 2 for Diabetic Macular Edema (DME) - Human Monoclonal Antibody Targeting eotaxin-1 - Oral Amphotericin B Delivery System JDRF, ISIS, AstraZeneca MedImmune & Immune Pharmaceuticals Efficient use of capital Experienced management & board 3
4 Validated Therapeutic Arena 104.5% return * Pfizer Santen Novartis Lpath (wamd) >$500 M Macusight $50 M upfront + undisclosed milestones ( wamd & DME) Genentech (wamd & DME) Undisclosed Bayer Regeneron (wamd & DME) >$320 M Sanofi-Aventis Fovea 370 M (DME & Other Ophthalmic Therapies) Alcon ThromboGenics 375 (VMA & Other Ophthalmic Therapies) Alcon Novartis Allergan ESBATech $589 M Alcon $12.9 B Molecular Partners $1.4 B (Ophthalmic Platform) (Ocular Drug and Device Pipeline) (wamd) DME = diabetic macular edema wamd = wet age-related macular degeneration * Last 12 Months, October 2012, BMO Capital Markets 4
5 ico 007 Novel 2 nd generation antisense candidate for the treatment of Diabetic Macular Edema Partner: Isis Pharmaceuticals
6 Diabetic Macular Edema (DME) Leading cause of blindness in working age adults Abnormal Retina Normal Retina Proliferation of new, permeable blood vessels allows blood to leak into retinal area, causing swelling and deformation Current treatments: Steroids Laser Anti-VEGF 6
7 ico-007: MOA - VEGF Plus Growth factors Modulate signal ico-007 inhibits the production of c-raf, thereby preventing the signaling of growth factors, which in turn prevents the production of new and permeable blood vessels Retina 7
8 ico-007 & C-Raf Kinase Recent results have shown that the pathways activated by Ras/Raf play a crucial role in diabetes-associated complications including retinopathy. 8
9 6 months Baseline Phase 1: Patient Examples Single Injection 110ug dose (sample patient) 350ug dose (sample patient) 700ug dose (sample patient) 1000ug dose (sample patient) 528 micron s 391 microns 867 microns 423 microns 379 microns 228 microns 124 microns 187 microns Delta: 149 microns Delta: 163 microns Delta: 743 microns Delta: 236 microns The number of patients in study is low, statistical significance cannot be inferred 9
10 ideal Physician-sponsored US Phase 2 Randomized, multi-center study Up to 208 patients 4 Study Groups Monotherapy dose 1 (350 ug) Monotherapy dose 2 (700 ug) Combination with Ranibizumab Combination Laser Photocoagulation 12 month follow up Initiated in Q Primary endpoint Change in visual Acuity Secondary endpoints Visual acuity & reduction of retinal thickness Duration of effect Safety of repeated injections Pharmacokinetic assessments (PK) 10
11 Competitive Landscape Category Product Device Anti-VEGF Steroids Laser Avastin Macugen Eylea Lucentis (approved) Iluvien, Ozurdex Triamcinolone, etc. Key Product Profile Issues Treatment burden Side effects Cost Biological targets 11
12 ico-007 Product Differentiation Novel c-raf kinase-targeted antisense specific for DME Targets more than just VEGF: Existing competitors target VEGF only, while DME is caused by multiple growth factors Longer half life = fewer injections: Competitors require monthly injections costly, time consuming and a logistical burden on both patients and physicians Easy to manufacture No known side effects comparable to select competitors 12
13 Market Opportunity U.S. Diabetes Patients 21 million 40 million 10 % Penetration % of diabetes patients report visual impairment (5.3 million Diabetic Retinopathy patients today) (1.6 million DME patients today) $ 500 $10,000 per annual treatment (only clinically significant cases) *Lucentis = $24,000 annually M 13
14 ico-007 Next Steps Received Health Canada Clearance for Phase 2 Completed fill finish manufacturing to produce clinical supply US FDA Clearance for Phase 2 US Phase 2 trial initiated August 2011 Interim results year end Ongoing regional partnership discussions 14
15 ico 008 Human monoclonal antibody treating both the back and front of the eye Partners: AstraZeneca/MedImmune & Immune Pharmaceuticals
16 ico-008 Human monoclonal antibody targeting eotaxin-1 Binds with high affinity to CCR3 Good safety & significant clinical history Ph 1 & 2 (n=126) Ocular: Vernal & Atopic Keratoconjunctivitis, Wet Age Related Macular Degeneration Systemic: Inflammatory Bowel Disease, Severe Asthma (License granted to Immune Pharmaceuticals) 16
17 ico 008 Licensing: MedImmune & Immune In-licensing $400,000 up front payment $7,000,000 milestone payments Exclusive rights to entire body Out-licensing $500,000 upfront received $32,000,000 incoming milestones 600,000 Immune shares 200,000 Immune warrants 6.14% ownership with dilution provisions Royalties on net sales Retained WW rights to all ocular applications 17
18 Oral Amphotericin B Delivery System Partner: The University of British Columbia
19 Amphotericin B & IV Delivery IT WORKS Gold standard AmBisome >$400M in sales Premium pricing for safety BUT NOT PRACTICAL IN MANY SITUATIONS Variety of Developed World fungal infections Lack of resources in Developing World Inconvenient unmet need: oral formulation 19
20 Proprietary Oral Delivery Platform Lipid capsule Candy Wrapper Proprietary platform Used for insoluble products including vaccines and proteins Expanding the Amp B market: Safety and convenience, HIV Oral treatment for : Goal of WHO & Gates Foundation, Governments & several other global health organizations Non-dilutive funding to date: CPDD/Gates and CIHR, NRC 20
21 Oral Amphotericin B Delivery System Studies HIV/AIDS currently managed using a combination of drugs (HAART) HIV often remains hidden in tissue reservoirs Amphotericin B may be efficient at flushing out latent HIV in reservoirs $1.1 million in non-dilutive grant funding from Canadian government/gates Foundation Next steps: feasibility testing, further pre-clinical studies and clinical trials 21
22 Financials & Corporate Review
23 ico Pipeline 23
24 Biotech Value Inflection: ico & Peers (as of Nov 1, 2012) Medicago $114.1 M Thrombogenics Lpath $68.5 M MethylGene $57.3 M ico $39.5 M $1,731.1 M Just received approval for Symptomatic Vitreomacular Adhesion (VMA) Other Biotech Value Drivers Partnerships SPA Other ico Value Drivers Ph 2 Interim data Partnerships Immune holdings IND Ph 1 data Ph 2 data Ph 3 final data NDA Approval 24
25 Upcoming Milestones Milestone Timing Completed ico 007: Complete fill finish manufacturing for clinical supply ico 007: US FDA Clearance for Phase 2 ico 007: US Phase 2 trial initiated ico 008: Licensed systemic rights to Immune Pharma $32+ Million Amp B: Non-dilutive grant funding ico 007: Interim results H ico 007: Regional partnership discussions ico 008: Pursuing non-dilutive funding of ocular programs 2012 YE Ongoing Ongoing Amp B: Phase 1 trial
26 Management and Directors Management Andrew Rae, MBA Co-founder, Director, President & CEO Peter Hnik, MD, MHSc. Chief Medical Officer John Meekison, BA, CIM, P. Log. Co-founder & Chief Financial Officer Non-Executive Directors William Jarosz, JD Chairman of the Board, ico Cartesian Capital Group, LLC Richard Barker, PhD Former Director General of the Association of the British Pharmaceutical Industry, Celgene director Noel Hall Co-founder of Aspreva Douglas Janzen Former President & CEO, Cardiome Strategic Advisory Board Donald Buell, MD ico-009 SAB Chair, Former Senior Medical Director, Astellas USA George Lasezkay, JD Principal, Turning Point Consultants, LLC, Former VP Corp Development, Allergan Extensive public company and life science experience Solid operational and product development expertise Ophthalmic specific expertise 26
27 Financials (as of June 30, 2012) Invested Capital to Date $22.5 million Largest Shareholders Cash Cash Runway Special Situations Funds (11%) Isis Pharmaceuticals (9.7%) Management (8.7%) $2.8 million *not including $1.1M grant Through Q (past interim data) Share Capital 52.7M (SO) 65.8M (FD) Head Office Vancouver BC, Canada Filings available at 27
28 ico Therapeutics TSX-V: ICO
CORPORATE PRESENTATION January 2019
CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current
More informationpsivida Corp PSDV June 2016
psivida Corp PSDV June 2016 Safe Harbor Statement Safe Harbor Statement SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking,
More informationRegeneron Reports Third Quarter 2010 Financial Results and Business Highlights
Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights TARRYTOWN, N.Y., Oct 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today
More informationOPT-302: A Novel Therapy for Eye Diseases
OPT-302: A Novel Therapy for Eye Diseases Corporate & Investor Presentation ASX Small & Mid-Cap Conference Sydney, September 6 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment in Opthea
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationFirst Quarter 2018 Financial Results. May 8, 2018
First Quarter 2018 Financial Results May 8, 2018 Agenda Introduction Sarah Carmody, Senior Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer First Quarter
More informationGaining Momentum in Gene Therapy
Gaining Momentum in Gene Therapy Corporate Presentation November 2018 Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial results
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationGaining Momentum in Gene Therapy
Gaining Momentum in Gene Therapy Corporate Deck March 6, 2019 Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial results that
More informationImmune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis
February 21, 2013 Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis Bertilimumab Targets Eotaxin-1, a Chemokine Over-Expressed in Ulcerative Colitis Patients HERZLIYA-PITUACH,
More informationAnti-VEGF for Neovascular AMD: An Insight Into The Future
Anti- for Neovascular AMD: An Insight Into The Future Hossam Zein, MBBCh Opthalmology Resident, Zagazig University Hospitals Where do we stand Anti- intravitreal injection is the current gold standard
More informationALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES
ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES Novel Development Programs for Potential Treatments of Serious Ocular
More informationi-bodies a new class of protein therapeutics to treat human disease
i-bodies a new class of protein therapeutics to treat human disease AGM November 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is
More informationPhylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
More informationPrograma Cooperación Farma-Biotech Neurociencias G79
G79 A Neuroprotective Therapy Barcelona, 15 de febrero 2011 Content 1. The Company 2. The Product a) Therapeutic focus b) Innovative mechanisms of action c) Differential features facing the market d) Current
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX. Updated July 2017
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Updated July 2017 Safe Harbor Statement This presentation (the Presentation ) includes forward looking statements within the meaning of the Private Securities Litigation
More informationLifeCycle Pharma A/S IMPROVING TREATMENTS IMPROVING LIVES. March 2011
LifeCycle Pharma A/S IMPROVING TREATMENTS IMPROVING LIVES March 2011 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. All statements other than statements of historical
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Safe Harbor Statement This presentation (the Presentation ) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationNYSE American: PFNX Corporate Presentation
NYSE American: PFNX Corporate Presentation Pfenex Safe Harbor Statement This presentation, including the accompanying oral presentation (the Presentation ), includes forward-looking statements within the
More informationvision is our mission NASDAQ: OPHT October 2018
vision is our mission NASDAQ: OPHT October 2018 Forward-looking Statements Any statements in this presentation about Ophthotech s future expectations, plans and prospects constitute forwardlooking statements
More informationARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationDiscovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology
20131009-03 Discovery of a First-In-Class Topically Bioavailable Kit Inhibitor With Clinical Activity Using Computational Chemogenomics Technology James Hendrix, Ph.D. President - Technology Med Chem &
More informationMANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 This management s discussion and analysis ( MD&A ) has been prepared
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationLifeCycle Pharma A/S IMPROVING TREATMENTS IMPROVING LIVES. January 2011
LifeCycle Pharma A/S IMPROVING TREATMENTS IMPROVING LIVES January 2011 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will,
More informationOPT-302: a VEGF-C/VEGF-D Trap for wet AMD
OPT-302: a VEGF-C/VEGF-D Trap for wet AMD Ophthalmology Innovation Summit, Nov 12 2015 Circadian Technologies (ASX:CIR, OTCQX:CKDXY) Megan Baldwin PhD, CEO & MD megan.baldwin@opthea.com 2 Disclaimer Investment
More informationCL King Best Ideas Conference
Leadership in Surface Modification and Drug Delivery Phil Ankeny, Senior Vice President and CFO CL King Best Ideas Conference The Omni Berkshire Place Hotel September 19, 2007 Safe Harbor Statement Some
More informationShareholder letter
Shareholder letter 2016-08-02 Dear shareholders, On February 3, 2016, the Xbrane share was listed on NASDAQ First North. Xbrane has since then executed on the company's business plan and delivered on the
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationMarch 13, Dear Shareholder:
15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 March 13, 2017 Dear Shareholder: We would like to take this time to report on the business activities and accomplishments of RegeneRx in
More informationImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
More informationRegeneron Reports Second Quarter 2010 Financial and Operating Results
Regeneron Reports Second Quarter 2010 Financial and Operating Results July 28, 2010 TARRYTOWN, N.Y., July 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN)
More informationAlliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd.
Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd. December 2, 2013 Background March 28, 2013 Capital alliance: DSP took a 1.5billion
More informationCorporate Presentation March 2017
Corporate Presentation March 2017 Safe Harbor Statement This presentation (the Presentation ) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
More informationLeading the world in novel adult stem cell therapies Half-Year Financial Results
Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following
More informationInnovative Non-Viral Gene Therapies for the Treatment of Ocular Diseases
Innovative Non-Viral Gene Therapies for the Treatment of Ocular Diseases Innovative Non-Viral Gene Therapies for the Treatment of Ocular Diseases Company Clinical stage company developing innovative non-viral
More informationJefferies Healthcare Conference. June 1, 2015
Jefferies Healthcare Conference June 1, 2015 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities
More information35 th Annual J.P. Morgan Healthcare Conference. Gwan Sun Lee. President & CEO
35 th Annual J.P. Morgan Healthcare Conference Gwan Sun Lee President & CEO This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses
More informationico Therapeutics Inc. ico-tsxv $0.59
EQUITY RESEARCH BIOTECHNOLOGY REPORT September 30, 2009 ico Therapeutics Inc. ico-tsxv $0.59 Connie S. Chen, PhD Research Analyst Biotechnology & Health Sciences 416-964-4448, cchen@lomltd.com Neal Belovay
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More informationOPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
OPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM031D July 2015 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-62296-123-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationMolecular Partners launches IPO on SIX Swiss Exchange
For release in Switzerland only. This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein. In particular,
More informationSetting: The Phase 1/2a study is being run under an Investigational New Drug (IND) program with the FDA at 14 sites across the US.
EURetina Late-Breaking Abstract A first-in-human Phase 1/2a study of the novel VEGF-C/D inhibitor OPT-302 alone and in combination with ranibizumab in patients with wet AMD Pravin Dugel, David Boyer, Andrew
More informationADVANCING A NOVEL TREATMENT FOR SEPTIC SHOCK INVESTOR UPDATE
ADVANCING A NOVEL TREATMENT FOR SEPTIC SHOCK INVESTOR UPDATE April 2017 1 Forward Looking Statements Certain statements contained in this presentation constitute forward-looking information within the
More informationNasdaq: MBRX. Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
Nasdaq: MBRX Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 November 14, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a
More informationDeveloping OPT-302: A novel therapy for wet AMD
Opthea Limited (ASX:OPT, OTCQX:CKDXY) Developing OPT-302: A novel therapy for wet AMD March 2016 Megan Baldwin PhD, CEO & Managing Director; megan.baldwin@opthea.com Disclaimer Investment in Opthea Limited
More informationQuo vadis Pharma industry. Vladimír Král, 2015
Quo vadis Pharma industry Vladimír Král, 2015 Steady flow of NCEs and lines extensions in the last years 58 4 15 39 2000 NBE New Combo + New Dosage Form + Vaccines NCE 49 11 14 24 2001 49 5 14 30 2002
More informationFourth Quarter and Full Year 2017 Financial Results. February 21, 2018
Fourth Quarter and Full Year 2017 Financial Results February 21, 2018 Agenda Introduction Sarah Carmody, Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer
More informationForesee Pharmaceuticals, Inc.
Foresee Pharmaceuticals, Inc. Rapid Development and Commercialization of a Proprietary Sustained-release Depot Formulation of Leuprolide for the Treatment of Advanced Prostate Cancer PNWBIO Meeting 10
More informationPain Therapeutics, Inc. Pain Therapeutics Announces Update on Drug Portfolio
For More Information Contact: Peter S. Roddy Vice President and Chief Financial Officer Pain Therapeutics, Inc. proddy@paintrials.com 512 501 2450 FOR IMMEDIATE RELEASE Pain Therapeutics Announces Update
More informationA Breakthrough Year Annual Report
A Breakthrough Year 2012 Annual Report The successful launch of EYLEA (aflibercept) Injection for the treatment of wet age-related macular degeneration has transformed Regeneron into a fully integrated
More informationPresentation to J.P. Morgan 33rd Annual Healthcare Conference. Moshe Manor President and CEO January 15, 2015
Presentation to J.P. Morgan 33rd Annual Healthcare Conference Moshe Manor President and CEO January 15, 2015 1 Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationAdvancing the Frontiers of mab mixtures
Advancing the Frontiers of mab mixtures...unlocking the power of the immune system Symphogen Corporate Presentation June 216 Symphogen/1 Symphogen Overview Privately held company - 125 employees Headquarters
More informationOphthalmology is our singular focus Akira Kurokawa President & CEO, Santen Pharmaceutical Co., Ltd.
Ophthalmology is our singular focus Akira Kurokawa President & CEO, Santen Pharmaceutical Co., Ltd. J.P. Morgan Healthcare Conference January 8, 2018 Disclosure Notice 2 Information given in presentation
More informationSpectral Medical Inc.
Spectral Medical Inc. Targeted therapy for septic shock March 2019 Forward Looking Statements Certain statements contained in this presentation constitute forward-looking information within the meaning
More informationA Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited
A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata or
More informationMarket Analysis & Segmentation. Gary Phillips CEO Bioshares 29 July 2016
Market Analysis & Segmentation Gary Phillips CEO Bioshares 29 July 2016 1 Forward looking statement This document contains forward looking statements, including statements concerning Pharmaxis future financial
More informationPlantForm Corporation
PlantForm Corporation Annual General Meeting September 21, 2010 Dr. Don Stewart President and CEO +1 (416) 452 7242 don.stewart@plantformcorp.com PlantForm Corporation 2010 www.plantformcorp.com The Opportunity
More informationNSE Grantees Meeting December 2015
NSE Grantees Meeting December 2015 The Spherical Nucleic Acid (SNA) Nanoparticle Changes the Paradigm for Oligo Therapeutics Linear DNA SNA Each company limited by chemistry, modality, and tissue of interest
More informationIntec. Pharma Unfolding drug delivery solutions. Investor Presentation. Nasdaq: NTEC. June 2017
Intec Pharma Unfolding drug delivery solutions Investor Presentation Nasdaq: NTEC June 2017 Forward Looking Statements This presentation by Intec Pharma Ltd. (referred to as we or our ) contains forward-looking
More informationFirst-in-Class Bispecific Antibodies For Cancer Immunotherapy
First-in-Class Bispecific Antibodies For Cancer Immunotherapy 2015 Company Highlights Vision Team Platform Pipeline Partners To dominate the bispecific antibody space in immunooncology through unique pipeline
More informationAflibercept (Eylea) Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A12-19 Aflibercept (Eylea) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Aflibercept (Eylea)
More informationFor personal use only
i-bodies a new class of protein therapeutics to treat human disease Biotech meets Broker: September 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment
More informationpsivida Transforms into Commercial Stage Specialty BioPharmaceutical Company ASCRS April 12, 2018 NASDAQ: EYPT
psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company OIS @ ASCRS April 12, 2018 NASDAQ: EYPT Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationCan-Fite Presentation January 2015
Can-Fite Presentation January 2015 1 Forward Looking Statement This presentation contains forward-looking statements, about Can-Fite s expectations, beliefs or intentions regarding, among other things,
More informationCorporate Presentation. Roberto Bellini President and Chief Executive Officer
Corporate Presentation Roberto Bellini President and Chief Executive Officer September 2012 Forward Looking Statement Certain statements contained in this presentation, other than statements of fact that
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationNYSE American: PFNX. Corporate Presentation November 2018
NYSE American: PFNX Corporate Presentation November 2018 Pfenex Safe Harbor Statement This presentation, including the accompanying oral presentation (the Presentation ), includes forward-looking statements
More informationCorporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationSECURITIES & EXCHANGE COMMISSION EDGAR FILING MYMETICS CORP. Form: 8-K. Date Filed:
SECURITIES & EXCHANGE COMMISSION EDGAR FILING MYMETICS CORP Form: 8-K Date Filed: 2018-04-23 Corporate Issuer CIK: 927761 Copyright 2018, Issuer Direct Corporation. All Right Reserved. Distribution of
More informationGlobal Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box. The purpose of this presentation Looking for Joint Venture
More informationINITIATOR PHARMA: HALF-YEAR REPORT 2017
INITIATOR PHARMA: HALF-YEAR REPORT 2017 Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was
More informationStrategic Collaboration with Amgen to develop MP0310
Strategic Collaboration with Amgen to develop MP0310 Patrick Amstutz, CEO Webcast of Molecular Partners AG, Switzerland (SIX: MOLN) December 19, 2018 2018 Molecular Partners AG Slide 1 Molecular Partners:
More informationConference call transcript for the March 2017 Quarterly Report
ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationThe Spanish biotech sector Case: ADVANCELL
In vitro models, reprofiling and nanomedicine for unmet medical needs The Spanish biotech sector Case: ADVANCELL SPAIN-LUXEMBURG ECONOMIC SEMINAR April 18th, 2007 1 ELEVATOR PITCH Product oriented, low
More informationA N N U A L R E P O R T
2 0 0 4 A N N U A L R E P O R T MISSION To develop and commercialize innovative pharmaceutical products based on active delivery molecules in order to effectively transport therapeutic drugs to their disease
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationAstellas to Acquire Agensys, Inc.
November 27, 2007 to Acquire, Inc. Japan, November 27, 2007 - Pharma Inc. ( ; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that its US subsidiary, US Holding, Inc. (headquarters:
More informationDon Stewart, PhD President and CEO (416)
PlantForm Corporation Don Stewart, PhD President and CEO (416) 452 7242 don.stewart@plantformcorp.com www.plantformcorp.com PlantForm Opportunity Proprietary, plant-based manufacturing of monoclonal antibody
More informationCorporate Presentation February 2016
Corporate Presentation February 2016 Issuer Free Writing Prospectus dated February 25, 2016 Filed Pursuant to Rule 433 Registration Statement No. 333 209454 Forward Looking Statements This presentation
More informationOPT-302: A novel therapy for Wet AMD
OPT-302: A novel therapy for Wet AMD Corporate Presentation, January 2017 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment in Opthea Limited ( Opthea ) is subject to investment risk, including
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationcompany overview M A R C H
company overview MARCH 2016 our focus INNOVATION in Aesthetics and Dermatology DISCOVERY CLINICAL DEVELOPMENT COMMERCIALIZATION 2 / CONFIDENTIAL and PROPRIETARY the sienna opportunity CLEAR STRATEGY for
More informationJefferies 2014 Global Healthcare Conference London, UK November 19, :00 AM. November
Jefferies 2014 Global Healthcare Conference London, UK November 19, 2014 10:00 AM November 2014 1 Forward Looking Statements This document contains "forward-looking statements" within the meaning of the
More informationVenture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013
Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program A FasterCures Webinar June 19, 2013 What is FasterCures? Founded in 2003, our mission is to save lives by saving
More informationFor personal use only
23 October 2013 ANP to Present at Canary BioTech and Healthcare Investor Roadshow Antisense Therapeutics Ltd. (ASX:ANP) today announced that CEO and Managing Director, Mark Diamond, has been invited to
More informationCorporate Presentation. June 2015
Corporate Presentation June 2015 Forward Looking Statement/Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions.
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationThe Pharmaceutical Technology Specialists.
The Pharmaceutical Technology Specialists www.drugdeliveryexperts.com Vision Center of excellence in pharmaceutical, delivery, device technology Incubator of technologies, companies, and talent Provider
More informationRegulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018
Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018 Rachel Witten, M.D. Medical Officer Office of Tissues and Advanced Therapies Center for
More information